Highlights
About
Liposome-based Nano Drugs
LipoCure is developing a number of therapeutics utilizing proprietary liposome-based nano drugs with novel drug-loading capabilities and drug-release mechanisms. LipoCure's proprietary platform implements an approach that allows for remote drug loading into nano-liposomes and concomitant controlled release of the drugs at the targeted site. This technology is designed to produce an enhanced permeability and retention effect, a significantly improved therapeutic effect, and reduced side effects. It can be used in conjunction with several well-established drugs used for the treatment of rheumatoid arthritis, multiple sclerosis, and cancer. LipoCure's founder is professor Yechezkel Barenholz, the co-developer of Doxil.
Identity
| Name | LipoCure |
|---|---|
| Slug | lipocure |
| Type / kind | startup |
| Crunchbase ID | lipocure |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN69u8cKDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Jerusalem District |
| HQ city | Jerusalem |
| HQ address | Hadassah Ein Kerem Campus, Jerusalem, Israel |
Web & social
| Website | http://lipocurerx.com/ |
|---|---|
| https://www.linkedin.com/company/3738990 |
Classifications
Funding
| Total raised | $8.0M |
|---|---|
| Current stage | Series A |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}